BEIJING, May 29, 2025 /PRNewswire/ -- Concord Healthcare Group Co., Ltd. ("Concord Healthcare"), a subsidiary of Concord Medical Services Holdings Limited (the "Company") (NYSE: CCM), which subsidiary is listed on the Main Board of The Stock Exchange of Hong Kong Limited (the "HKSE") under the stock code 2453.HK, announced that Concord Healthcare had made important progress in precise tumor diagnosis and treatment technology. Concord Healthcare's self-developed large language model ("LLM") in the vertical f ...

4月29日，泰和诚医疗(CCM)盘中上涨2.5%，截至21:39，报6.16美元/股，成交4.86万美元，总市值 2674.50万美元。 本文源自：金融界 作者：行情君 4月18日，泰和诚医疗将披露2024财年年报（数据来源于纳斯达克官网，预计披露日期为美国当地时 间，实际披露日期以公司公告为准）。 资料显示，泰和诚医疗集团有限公司是由JP摩根、摩根士丹利和中金公司联合推荐,于2009年在美国纽 约证券交易所上市、以医疗服务为主营业务的控股企业。成立于1997年的泰和诚是一家专业从事癌症预 防、诊疗、教育和研究的医疗服务提供商,主营业务包括提供第三方肿瘤影像诊断与放射治疗服务,自建 自营肿瘤专科医院、肿瘤门诊部、独立影像中心及独立质子中心。 2015年,泰和诚与美国得克萨斯大学MD安德森癌症中心签署长期战略合作协议,双方将在诊疗技术、放 疗质控、医疗流程、运营管理、新加坡&中国大陆的品牌使用以及质子中心运营和培训等多个层面展开 深入合作,共同建设以多学科诊疗模式为基础、以临床研究为导向、具有亚学科专长的国际化肿瘤专科 医院,优化患者就医体验,提高中国肿瘤诊疗水平。 财务数据显示，截至2024年06月30日，泰 ...

Core Viewpoint - Concord Medical Services Holdings Limited has filed its annual report for the fiscal year ended December 31, 2024, with the U.S. Securities and Exchange Commission, highlighting its commitment to transparency and regulatory compliance [1]. Company Overview - Concord Medical is a healthcare provider specializing in a full cycle of premium oncology services, including cancer diagnosis, treatment, education, and prevention [2]. - The company focuses on multidisciplinary cancer care and operates cancer hospitals equipped with advanced technology, such as a state-of-the-art proton therapy system [2]. - Concord Medical aims to enhance the quality and accessibility of cancer care through its network of self-owned and partnered hospitals and clinics across China [2].

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC ...

Core Viewpoint - Concord Medical Services Holdings Limited, a healthcare provider specializing in cancer treatment, announced the adoption of the Fifth Amended and Restated Memorandum and Articles of Association during its 2024 annual general meeting of shareholders held on December 27, 2024 [1]. Group 1: Company Overview - Concord Medical provides a full cycle of premium oncology services, including cancer diagnosis, treatment, education, and prevention [2]. - The company focuses on multidisciplinary cancer care and operates cancer hospitals equipped with advanced technology, such as a state-of-the-art proton therapy system [2]. - Concord Medical aims to enhance the quality and accessibility of cancer care through its network of self-owned hospitals and partnered facilities across China [2].

Group 1 - Concord Medical Services Holdings Limited will hold its 2024 annual general meeting of shareholders on December 27, 2024, at 10:00 a.m. Beijing Time [1] - The purpose of the meeting includes amending the Company's memorandum and articles of association to reflect the change in the ratio of its American depositary shares to Class A ordinary shares, effective July 30, 2024 [2] - Shareholders will have the opportunity to discuss Company affairs with management during the meeting [2] Group 2 - Concord Medical is a healthcare provider specializing in a full cycle of premium oncology services, including cancer diagnosis, treatment, education, and prevention [3] - The Company aims to improve the quality and accessibility of cancer care through its network of self-owned cancer hospitals and clinics, as well as partnered hospitals across China [3] - Concord Medical is equipped with technologically advanced equipment, such as a state-of-the-art proton therapy system [3]

Core Insights - Concord Medical Services Holdings Limited announced that its subsidiary, Guangzhou Concord Cancer Center, has obtained a large medical equipment procurement license for its proton equipment, enabling it to offer proton therapy treatment services [1][2][3] Group 1: Company Developments - Guangzhou Hospital completed the installation of proton equipment in September 2020 and began clinical trials in November 2022 [2] - The National Health Commission of the PRC approved Guangzhou Hospital's application for the procurement license on September 14, 2024, allowing the hospital to start proton therapy services soon [2] - Concord Healthcare, a subsidiary of Concord Medical, also confirmed the receipt of the license for Guangzhou Hospital on September 15, 2024 [3] Group 2: Company Overview - Concord Medical provides a full cycle of premium oncology services, including cancer diagnosis, treatment, education, and prevention, focusing on multidisciplinary cancer care [4] - The company aims to enhance the quality and accessibility of cancer care through its network of self-owned and partnered hospitals across China [4] - Concord Healthcare serves cancer patients through both self-owned and third-party medical institutions, offering a comprehensive range of oncology healthcare services [5]

Group 1 - Concord Medical Services Holdings Limited has regained compliance with the NYSE's minimum average share price requirement of US$1.00 over a 30 trading-day period, as notified by the NYSE on August 6, 2024 [1] - The company had previously received a compliance notice from the NYSE on February 12, 2024, indicating it was below the compliance standards due to the trading price of its American Depositary Shares [1] Group 2 - Concord Medical is a healthcare provider specializing in a full cycle of premium oncology services, including cancer diagnosis, treatment, education, and prevention [2] - The company aims to improve the quality and accessibility of cancer care through its network of self-owned cancer hospitals and clinics, as well as partnered hospitals across China [2] - Concord Healthcare, a subsidiary of Concord Medical, provides oncology healthcare services through both self-owned and third-party medical institutions, focusing on precision radiation therapy and integrated oncology-related services [3]

Core Viewpoint - Concord Medical Services Holdings Limited plans to change the ratio of its American depositary shares (ADSs) to Class A ordinary shares from 1 ADS representing 3 Class A shares to 1 ADS representing 30 Class A shares, effective July 30, 2024 [1][2] Group 1: ADS Ratio Change - The change in the ADS Ratio will be equivalent to a one-for-ten reverse ADS split, requiring ADS holders to exchange every 10 existing ADSs for 1 new ADS [1] - No fractional new ADSs will be issued; instead, fractional entitlements will be aggregated and sold, with net cash proceeds distributed to ADS holders [2] - The change in the ADS Ratio is expected to increase the ADS trading price proportionally, although no assurance can be given regarding the exact price post-change [2] Group 2: Company Overview - Concord Medical is a healthcare provider specializing in a full cycle of oncology services, including cancer diagnosis, treatment, education, and prevention [3] - The company aims to enhance the quality and accessibility of cancer care through its network of self-owned and partnered hospitals across China [3] - Concord Healthcare, a subsidiary, provides oncology healthcare services and medical equipment to both self-owned and third-party medical institutions [4]

Financial Reporting - Concord Healthcare filed its annual report for the year ended December 31, 2023, on April 19, 2024[4] Stock Market Activity - Concord Healthcare's H shares were listed on the HKSE on January 9, 2024[4]